TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
-0.34%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.63B
AUM Growth
-$21.2M
(-0.8%)
Cap. Flow
+$36.2M
Cap. Flow
% of AUM
1.38%
Top 10 Holdings %
Top 10 Hldgs %
39.68%
Holding
190
New
18
Increased
27
Reduced
27
Closed
13
Top Buys
| 1 |
Elevance Health
ELV
|
$45.7M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$22.8M |
| 3 |
Sarepta Therapeutics
SRPT
|
$19.9M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$18.2M |
| 5 |
Exelixis
EXEL
|
$14.1M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$47.2M |
| 2 |
Stryker
SYK
|
$26.4M |
| 3 |
Zimmer Biomet
ZBH
|
$24.7M |
| 4 |
Lantheus
LNTH
|
$21.7M |
| 5 |
Humana
HUM
|
$19.9M |
Sector Composition
| 1 | Healthcare | 96.54% |
| 2 | Real Estate | 2.01% |
| 3 | Industrials | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Neurocrine Biosciences
NBIX
$13.5B
| $11.4M | 0.44% |
112,908
| – | – |
|
52
SPDR S&P Biotech ETF
XBI
$5.29B
| $11.3M | 0.43% |
147,677
| – | – |
|
53
Guardant Health
GH
$8.11B
| $11.1M | 0.42% |
472,184
| – | – |
|
54
Rallybio
RLYB
$24.1M
| $9.86M | 0.38% |
1,727,067
| – | – |
|
55
Avantor
AVTR
$8.74B
| $9.71M | 0.37% |
459,488
| – | – |
|
|
KRTX
56
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $9.71M | 0.37% |
53,452
| – | – |
|
57
Travere Therapeutics
TVTX
$1.75B
| $9.41M | 0.36% |
418,520
| – | – |
|
|
ITCI
58
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $9.33M | 0.36% |
172,371
| – | – |
|
59
Labcorp
LH
$22.8B
| $9.19M | 0.35% |
46,609
-4,772
| -9% | -$941K |
|
60
Apellis Pharmaceuticals
APLS
$3.51B
| $8.91M | 0.34% |
135,124
+68,698
| +103% | +$4.53M |
|
61
Alkermes
ALKS
$4.95B
| $8.73M | 0.33% |
309,613
| – | – |
|
|
62
Zimmer Biomet
ZBH
$20.8B
| $8.7M | 0.33% |
67,356
-191,512
| -74% | -$24.7M |
|
63
Omega Healthcare
OHI
$12.5B
| $8.4M | 0.32% |
306,433
| – | – |
|
64
Cytokinetics
CYTK
$5.98B
| $7.71M | 0.29% |
219,025
+143,886
| +191% | +$5.06M |
|
65
Denali Therapeutics
DNLI
$2.24B
| $7.48M | 0.28% |
324,829
+52,309
| +19% | +$1.21M |
|
66
CVS Health
CVS
$93B
| $6.96M | 0.26% |
93,621
| – | – |
|
67
Sanofi
SNY
$122B
| $6.72M | 0.26% |
123,454
| – | – |
|
|
68
Lantheus
LNTH
$3.75B
| $6.56M | 0.25% |
79,495
-263,377
| -77% | -$21.7M |
|
|
LTC
69
LTC Properties
LTC
$1.67B
| $6.4M | 0.24% |
182,293
| – | – |
|
70
Agilent Technologies
A
$35.5B
| $5.98M | 0.23% |
43,191
| – | – |
|
71
Steris
STE
$23.9B
| $5.94M | 0.23% |
31,072
+14,403
| +86% | +$2.76M |
|
72
Sabra Healthcare REIT
SBRA
$4.56B
| $5.87M | 0.22% |
510,660
| – | – |
|
|
VECT
73
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $5.87M | 0.22% |
682,834
-54,870
| -7% | -$472K |
|
74
Intellia Therapeutics
NTLA
$1.26B
| $5.75M | 0.22% |
154,269
| – | – |
|
|
MDRX
75
DELISTED
Veradigm Inc. Common Stock
MDRX
| $5.59M | 0.21% |
428,580
| – | – |
|